According to a leading Colorado prostate cancer expert, after a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease. The drugs have different and innovative methods of action. The first drug is a bone protective agent, the second is a more effective hormone agent, third is a new form of radiotherapy and the final one is the first drug tested for cancer immunotherapy. David Crawford, MD, investigator at the University of Colorado Cancer Center, notes that these drugs are being approved for use only in patients who have had more established therapies fail and hopes that in coming years science may accelerate the use of these drugs to first-line therapies.